446880-83-7

Usage

Uses

Used in Organic Synthesis:
2-bromo-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions and the formation of new compounds with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-bromo-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine is utilized as a starting material for the development of new drugs. Its distinctive molecular structure may contribute to the discovery of innovative therapeutic agents with novel mechanisms of action.
Used in Material Science:
2-bromo-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine may also find applications in material science, where its unique properties could be harnessed to develop new materials with specific characteristics, such as improved conductivity, stability, or reactivity.
Used in Chemical Research:
The synthesis and characterization of 2-bromo-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine are of significant interest to chemists and researchers. Its complex structure provides a platform for studying various chemical reactions and understanding the underlying mechanisms, which can further advance the field of chemistry.

Upstream product

• 2524-52-9 ethyl-2-picolinate 
• 4926-28-7 2-Bromo-4-picoline 
• 446852-65-9 2-(2-bromopyridin-4-yl)-1-(pyridin-2-yl)ethan-1-one 
• 446880-81-5 2-bromo-4-(3-(pyridine-2-yl)-1H-pyrazol-4-yl)pyridine 
• 76-83-5 trityl chloride 

Downstream Products

• 452343-18-9 4-[4-(3-pyridin-2-yl-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl]benzoic acid 
• 1333492-65-1 2-(1-methyl-1H-pyrazol-4-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-61-7 2-phenyl-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-66-2 2-(3-methoxyphenyl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-64-0 5-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)-pyrimidine 
• 1333492-63-9 3-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)-quinoline 
• 1333492-62-8 4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,3'-bipyridine 
• 1333492-67-3 2-(2-methoxyphenyl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridine 
• 1333492-71-9 4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,2'-bipyridine 
• 1333492-68-4 8-(4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)pyridin-2-yl)quinoline 
• 1333492-69-5 N,N-dimethyl-3-((4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-[2,3'-bipyridin]-6'-yl)-oxy)propan-1-amine 
• 1333492-70-8 6'-(4-methylpiperazin-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-2,3'-bipyridine 
• 452342-37-9 2-phenyl-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine 
• 1333492-73-1 2-(1H-imidazol-1-yl)-4-(3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl)-pyridine 

Relevant academic research and scientific papers

ALK5 INHIBITOR CONJUGATES AND USES THEREOF

The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibr

ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.

2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling

Novel inhibitors of TGF-β1 and activin A signalling based on a 2-aryl-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine pharmacophore have been synthesised. Compounds containing phenyl or aromatic nitrogen heterocycle substituents inhibited both types of signalling with HEK-293T cells in culture, with a selectivity preference for TGF-β1. Synthetic compounds containing pyridin-3-yl, pyrazol-4-yl, pyrazol-1-yl or 1H-imidazoyl-1-yl substituents exhibited structural and functional attributes suitable for further investigation related to the development of more potent TGF-β inhibitors.

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N- (tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor

Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.